THE LIBRARY: EBOOK
Single Use Technology: From Bioprocess Convenience to Drug-Development Driver
In order to accelerate the production of biological molecules, companies have been exploring disposable, single-use systems. Download this ebook to learn the impact and future use of single-use technologies, cost-saving opportunities, and challenges of implementing new drug development processes.
Latest Commentary
EVENTS
- BioImmersion Three-Day CourseJuly 10-12 — Chicago, IL
- BioBasics: Biotech for the Non-ScientistSeptember 16-17 — Boston, MA
- BioImmersion Three-Day CourseOctober 16-18 — Washington, D.C.
Press Releases
- Thought-Leader Opinion and Clinical Data Indicate that Emerging Agents from Two Drug Classes Have Efficacy Advantages Over Currently Used Therapies for HR-Positive, HER2-Negative Breast Cancer
- IsoRay Announces A New International Distributor For Greece
- Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent
- Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent
- Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system
- More Press Releases
Featured Jobs
-
Sr. Manufacturing Process Lead Job
Celgene Corporation - Basking Ridge NJ US -
Research Associate - Biochemistry
Syros Pharmaceuticals - Watertown Massachusetts -
Associate Manager, Commercial Specs – Global Reg CMC Job
Celgene Corporation - Basking Ridge NJ US -
Manager Regulatory Affairs
Qualitest Pharmaceuticals - -
Sr. Manager, Market Access Marketing
Regeneron Pharmaceuticals - Tarrytown NY
New biweekly email newsletter frequency
Biomarkers making a difference in clinical trials
Biomarkers play a major role in personalized medicine, supporting diagnosis and identifying those patients who are (or aren't) likely to respond, and supporting drugs through clinical trials.
Protein biomarkers: Here's a view from Sweden
Ulf Landegren, professor of molecular medicine at Uppsala University and vice chair of the Science for Life Laboratory (SciLifeLab), spoke with FierceBiomarkers at the BBMRI.se HandsOn: Biobanks meeting in Uppsala, Sweden, giving a taste of his views and his work in protein biomarkers. Here is a snapshot of the conversation.
Genetic biomarkers and the frets of the 'worried well'
As genetic tests become more widely available, some people are concerned that they are swelling the ranks and the anxiety levels of the "worried well"--the healthy people who visit the doctor to get reassurance, and can now get online genetic tests to confirm or assuage their worries.
Inform Genomics: Personalized medicine uses genetic markers with a twist
A recently formed privately funded startup, Inform Genomics, is taking the concept of genetic markers and giving it a new twist, Ed Rubenstein, president and CEO, told FierceBiomarkers.
The ethics of Alzheimer's risk testing
Biomarker tests are being developed and used that can improve diagnosis and predict the chance of developing the disease. However, knowing the potential risk of Alzheimer's disease can lead to anxiety and depression in people who have not developed symptoms. So is their use ethical, when patients may not be able to do anything with the results other than wait for symptoms and wonder about the future?
Personalized medicine: AstraZeneca's view at BIO 2012
At AstraZeneca, the concept of personalized medicine is becoming embedded in R&D, Glenn Miller, vice president and head of personalized medicine at AstraZeneca, told FierceBiomarkers at BIO 2012.
The ethics of finding markers in a fetal genome
The recent non-invasive sequencing of an unborn baby's genome, using cell-free fetal DNA in the mother's bloodstream, found a range of mutations in the child's genome that were not seen in either of the parents. However, it has raised a lot of ethical issues, too, with a mixed and emotional response across the blogosphere.
Jury is still out on value of genetic biomarkers
This week's newsletter features a number of stories about gene-based biomarkers, and there has been an explosion in these since the sequencing of the human genome over a decade ago. But the jury is still out on genetic testing.
Targeted therapies need cost-effective biomarkers
Biomarker discovery and development are driving the development of targeted therapies, particularly in cancer, and these need companion tests to ensure that only the people with the right markers (and therefore the people who are most likely to benefit) are treated. But what does it cost?